Earnings call transcript: Eckert & Ziegler H1 2026 profit rises as growth stays mixed

Eckert & Ziegler reported flat revenue of EUR 150 million for H1 2026, holding steady at EUR 320 million for the full year. Despite this, the company's adjusted EBIT rose to EUR 33 million, marking a 5% increase in net income. The medical segment led the revenue with 55% of total sales and 64% of adjusted EBIT, boasting an adjusted EBIT margin above 30%.

In contrast, the isotope products business saw a 24% decline in adjusted EBIT due to a weaker product mix and lower industrial demand. Management remains confident in meeting the full-year guidance, citing a strategic shift towards radiopharmaceutical growth, particularly in lutetium, Y-90, and actinium products. The company's financial health is reinforced by a strong cash position, with Eckert & Ziegler holding more cash than debt on its balance sheet.

Despite a modest stock decline of 0.77% to $13.545, investors appear cautious, with the shares trading near their 52-week low.